See the Real Week 32, 2026 Issue — In Full
Using the actual Week 32 issue (coverage 2026-07-30 to 2026-08-05), this page shows you exactly what’s inside all three deliverables, and exactly what each plan tier includes. No account, no payment details, no catch.
Unlike our weekly issues, this page carries no redactions. Every excerpt below is pulled directly from the real Week 32 Individual Report (26 pages), Approval Letter Collection (10 pages), and Excel data set (10 sheets).
26 pages covering drug approvals, device clearances, recalls, and Warning Letters, with our signature Asian Company Watch section.
The original FDA approval letters and PMA order statements behind this week’s headline cases — verbatim source documents.
Every new drug approval, device clearance, recall, Warning Letter, and application history, in 10 structured sheets.
Inside the Weekly Report (26 pages)
Beyond the standard drug/device/recall coverage every edition has, the English edition’s signature section is Asian Company Watch — every FDA approval or clearance touching a Japanese, South Korean, Chinese, Taiwanese, or Indian company that week, each with a one-line “Intelligence” note on the competitive implication, plus filer history and predicate-device tracking for medical devices.
| Target Date | Product | Company | Indication |
|---|---|---|---|
| 2026-08-17 | iberdomide | Bristol Myers Squibb | Relapsed/refractory multiple myeloma |
| 2026-08-22 | Deramiocel | Capricor Therapeutics | Cardiomyopathy in DMD |
| 2026-09-22 | Zilganersen | Ionis Pharmaceuticals | Alexander disease |
| 2026-11-30 | Povetacicept | Vertex | IgA nephropathy |
Inside the Approval Letter Collection (10 pages, 4 cases)
For this week’s headline cases — new drug approvals, efficacy supplements, and major PMA Original/Panel-Track devices — we compile the primary FDA-published source document itself (the official approval letter, or PMA approval-order statement), not a paraphrase. Long letters are excerpted for length, with a link to the full text on FDA’s official page.
“This NDA provides for the use of Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients. We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling. […] The scheduling of this product in accordance with the CSA (21 U.S.C. 811) is not yet complete as of the date of this letter. Therefore […] Orzeyful may be marketed only after DEA has published the notice in the Federal Register.”
What’s in the FDA Database (10 sheets)
Every new drug approval, efficacy supplement, device clearance (510(k)/PMA), Warning Letter, and recall FDA published that week, broken out by sheet, with each row’s extraction criteria stated explicitly — the article text is a curated excerpt; the Excel file is the full set.
On AI Hallucination Safeguards
Generative AI carries an inherent risk of producing plausible-sounding but false claims. We prioritize accuracy over speed, with the following design and process controls.
No claim without a source
The AI is not permitted to generate claims absent from primary-source text. Failed extractions are stated as such, not filled in.
Automated cross-check
Generated text is mechanically checked against the primary source; unsupported statements are automatically flagged and removed.
Key items verified against the letter
New drug approvals and major efficacy supplements are checked against the actual FDA approval letter before being described.
Who This Report Is For
Plans
All plans include the Weekly Report PDF, the Approval Letter Collection, and the Excel data set. What differs between plans is who can access each edition.
| Individual | Team | Corporate | |
|---|---|---|---|
| ① Weekly Report | ✓ | ✓ | ✓ |
| ② Approval Letter Collection | ✓ | ✓ | ✓ |
| ③ FDA Database (Excel) | ✓ | ✓ | ✓ |
| ④ Sharing | You only | Up to 5 users, same organization | Unlimited within one designated affiliate (all 5 languages) |
| Price | $89 / mo | $350 / mo〜 | $8,900 / yr |
Try All Three Deliverables From the Week 32 Issue, Free
No account, no payment details required. Everything described above, as the real files.
↓ ① Weekly Report — download (PDF · 26 pages) ↓ ② Approval Letter Collection — download (PDF · 10 pages) ↓ ③ FDA Database — download (Excel · 10 sheets)